Lee Chan Henry sold $157K of ONC

Lee Chan Henry (SVP, General Counsel) sold 590 shares of BeOne Medicines Ltd. (ONC) at $265.98 ($0.16M total) on 2026-06-16.

Original reporting
SEC EDGAR · Lee Chan Henry
Published Jun 18, 2026, 9:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, date, and post-transaction holdings (0 shares).

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change fundamentals or provide new operational/financial guidance.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no context on prior grants, vesting schedules, or whether other insiders/funds are trading—so signal-to-noise is low.

Relevance 4/10Novelty 5/10Timing: after-hours/filing update on 2026-06-18 (SEC EDGAR Form 4)

Background

This is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

SEC Form 4 shows ONC’s SVP & General Counsel Lee Chan Henry sold 590 shares on 2026-06-16 for $156,925.25.

Expected impact

Likely limited near-term impact; any reaction should be small and short-lived unless followed by additional insider activity or company-specific news.

Evidence & confidence

The filing is primary-source and specific, but the transaction is a relatively small, single insider sale with no accompanying company event or guidance change in the text.

Market effects

Minimal; this is company-specific insider trading with no sector-wide regulatory/clinical/financing signal in the text.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity/tax-driven and not predictive, especially since the filing does not cite any adverse company development.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ONC).

  • Lee Chan Henry

    SVP, General Counsel; sold 590 shares on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONCMed

BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

$ONCMed

BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma

BeOne Medicines (ONC) announced FDA Priority Review for BRUKINSA (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, based on Phase 3 MANGROVE trial results showing 43% reduced risk of disease progression or death. If approved, it would be the first chemotherapy-free regimen for this indication. The company is also seeking approvals in Europe and China. BRUKINSA is already approved for other B-cell malignancies.